The reiteration of an Overweight rating by Cantor Fitzgerald's analyst Louise Chen indicates a positive outlook for Roivant Sciences. This rating, along with the maintained $15 price target, suggests that the stock is expected to outperform the market in the short term, which could lead to an increase in its stock price.